Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity (Q45698037)

15 December 2017

title

Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity (English)

1 reference

15 December 2017

3

1 reference

15 December 2017

Martha Campbell-Thompson

10

1 reference

15 December 2017

Zhang YC

1

1 reference

15 December 2017

Powers M

2

1 reference

15 December 2017

Brusko T

4

1 reference

15 December 2017

Song S

5

1 reference

15 December 2017

Flotte T

6

1 reference

15 December 2017

Snyder RO

7

1 reference

15 December 2017

Potter M

8

1 reference

15 December 2017

Scott-Jorgensen M

9

1 reference

15 December 2017

Crawford JM

11

1 reference

15 December 2017

Nick HS

12

1 reference

15 December 2017

Agarwal A

13

1 reference

15 December 2017

Ellis TM

14

1 reference

15 December 2017

Atkinson MA

15

1 reference

15 December 2017

publication date

1 February 2004

1 reference

15 December 2017

1 reference

15 December 2017

volume

11

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

233-240

1 reference

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Gene therapy. Viral vectors still pack surprises

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Cross-species comparison of in vivo reporter gene expression after recombinant adeno-associated virus-mediated retinal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Immune responses to adenovirus and adeno-associated virus in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Strain-based genetic differences regulate the efficiency of systemic gene delivery as well as expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Strain variation in the IgG1 antibody response to proteins administered intranasally in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Production and purification of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

inferred from DOI database lookup

7 January 2021

based on heuristic

Strain-dependent antibody response induced by DNA immunization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302144

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3302144

1 reference

Dimensions Publication ID

15 December 2017

1026631697

0 references

1 reference